Precision 360 Degree Approach to GLP-1 Management Helps Reduce Costs for Employers, Improves Results for Employees

Payer Matrix, Cecelia Health and Blue Genes Lab partner to combine genetic screening, clinical support and approval oversight with brand-name GLP-1s at half the price of standard coverage

PHOENIX, Nov. 4, 2026 /PRNewswire/ -- Payer Matrix, Cecelia Health and Blue Genes Lab today announced a new integrated medication management program, PreciselyRx, to help self-funded employers manage GLP-1 coverage from the first prescription through the first year of therapy.

Obesity is a leading driver of chronic conditions, such as diabetes and heart disease. GLP-1 medications can help many people achieve meaningful weight loss, but their cost—up to a third of an employer's annual prescription drug spend—creates difficult coverage decisions for employers. Managing that investment requires more than controlling the price of each prescription; it also requires informed treatment decisions and support throughout therapy. PreciselyRx enables employers to capture the health benefits and medical cost savings associated with brand name GLP-1s at approximately half the cost of standard GLP-1 coverage. 

PreciselyRx addresses four major sources of medication-related waste by combining rigorous approval controls, pre-treatment genetic screening, sourcing at the lowest available net cost, and 12 months of clinical support. Together, these services help reduce ineffective treatment starts, lower the cost of each fill, mitigate adverse side effects that can lead to additional healthcare utilization, and improve persistence so therapies have the opportunity to deliver their intended results.

By integrating these capabilities into a single program, PreciselyRx delivers greater price transparency and upfront savings, eliminates the complexity and delays associated with rebate accounting, and provides members with ongoing clinical support throughout their treatment journey.

For employers, the result is a more disciplined approach to GLP-1 coverage that aligns clinical appropriateness with financial stewardship. Genetic screening provides additional insight into how members may respond to treatment, helping inform prescribing decisions and care plans. The prescriber retains full authority to make the final medically appropriate treatment decision.

Members enrolled in PreciselyRx receive ongoing clinician-led support designed to improve adherence, help manage side effects and reinforce healthy behavior changes that contribute to long-term success. This personalized, lifestyle-driven approach helps members stay engaged in treatment while giving employers greater confidence that their investment in GLP-1 therapy is producing meaningful outcomes.

"Employers shouldn't have to choose between covering GLP-1s and controlling their pharmacy budget," said Jennifer Hoefner, Chief Executive Officer, Payer Matrix. "We help employers access lower cost, brand-name GLP-1s for their employees, and support employees throughout their therapy to aid in adherence and monitor any adverse side effects."

"Employers are paying for GLP-1s that were never going to work for some members," said Nick Glimcher, Chief Executive Officer, Blue Genes Lab. "We can identify many of those members before the first prescription is filled, saving employees time, frustration and out-of-pocket costs, and saving employers expense that benefits no one." 

"Starting the right medication the first time is only the initial step. Cecelia Health's clinical team helps members manage side effects, build healthy habits, and stay engaged in treatment, while working with prescribing providers to support safe, effective care," said Mark Clermont, Chief Executive Officer, Cecelia Health. "With personalized, clinician-led support, members can achieve meaningful results—people under our care see an average of 18% weight loss."

PreciselyRx is available now to self-funded employers and health and welfare funds nationwide.

To learn more, visit PreciselyRx.com.

Genetic results reflect statistical association, not deterministic prediction. They do not diagnose any condition or replace the judgment of the prescribing clinician. Testing is performed by GTI Laboratories, a CLIA-certified, CAP-accredited laboratory.

About Payer Matrix
Payer Matrix is a concierge medication cost containment solution that has focused on high-cost specialty medications since 2016. We are now expanding our offerings to include solutions for GLP-1 non-specialty medications. Working with more than 40 PBMs and 30 TPAs, Payer Matrix delivers a high-touch, member-centric experience that helps reduce prescription costs for both plan sponsors and members.

About Blue Genes Lab
Blue Genes Lab provides genetic testing that helps health plans, employers and consumers choose medications and health products that are more likely to work. Its pharmacogenomic platform screens more than 500 medications for drug–gene interactions, including GLP-1s and 65 high-cost specialty drugs. Testing is performed by GTI Laboratories, a CLIA-certified, CAP-accredited laboratory. Blue Genes Lab is based in Phoenix, Arizona. Learn more at bluegeneslab.com.

About Cecelia Health
Cecelia Health is a national virtual specialty medical practice serving people with chronic conditions across the care continuum. We expand access to care and provide personalized clinical support to help patients achieve sustained engagement and durable outcomes. Powered by digital tools and uniquely data-enabled, our integrated care approach addresses the whole person with proactive, coordinated support focused on clinical, behavioral, social, and emotional needs across cardiometabolic and related conditions. Following evidence-based guidelines and clinical best practices, our solution is scalable for health plans, providers, health systems, and life sciences.

SOURCE Blue Genes Lab